Phenotypical variability and atypical presentations in a French cohort of Andersen-Tawil syndrome.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
08 2022
Historique:
revised: 31 03 2022
received: 27 01 2022
accepted: 18 04 2022
pubmed: 24 4 2022
medline: 19 7 2022
entrez: 23 4 2022
Statut: ppublish

Résumé

Andersen-Tawil syndrome (ATS) is a skeletal muscle channelopathy caused by KCNJ2 mutations, characterized by a clinical triad of periodic paralysis, cardiac arrhythmias and dysmorphism. The muscle phenotype, particularly the atypical forms with prominent permanent weakness or predominantly painful symptoms, remains incompletely characterized. A retrospective clinical, histological, electroneuromyography (ENMG) and genetic analysis of molecularly confirmed ATS patients, diagnosed and followed up at neuromuscular reference centers in France, was conducted. Thirty-five patients from 27 unrelated families carrying 17 different missense KCNJ2 mutations (four novel mutations) and a heterozygous KCNJ2 duplication are reported. The typical triad was observed in 42.9% of patients. Cardiac abnormalities were observed in 65.7%: 56.5% asymptomatic and 39.1% requiring antiarrhythmic drugs. 71.4% of patients exhibited dysmorphic features. Muscle symptoms were reported in 85.7%, amongst whom 13.3% had no cardiopathy and 33.3% no dysmorphic features. Periodic paralysis was present in 80% and was significantly more frequent in men. Common triggers were exercise, immobility and carbohydrate-rich diet. Ictal serum potassium concentrations were low in 53.6%. Of the 35 patients, 45.7% had permanent weakness affecting proximal muscles, which was mild and stable or slowly progressive over several decades. Four patients presented with exercise-induced pain and myalgia attacks. Diagnostic delay was 14.4 ± 9.5 years. ENMG long-exercise test performed in 25 patients (71.4%) showed in all a decremental response up to 40%. Muscle biopsy performed in 12 patients revealed tubular aggregates in six patients (associated in two of them with vacuolar lesions), dystrophic features in one patient and non-specific myopathic features in one patient; it was normal in four patients. Recognition of atypical features (exercise-induced pain or myalgia and permanent weakness) along with any of the elements of the triad should arouse suspicion. The ENMG long-exercise test has a high diagnostic yield and should be performed. Early diagnosis is of utmost importance to improve disease prognosis.

Sections du résumé

BACKGROUND AND PURPOSE
Andersen-Tawil syndrome (ATS) is a skeletal muscle channelopathy caused by KCNJ2 mutations, characterized by a clinical triad of periodic paralysis, cardiac arrhythmias and dysmorphism. The muscle phenotype, particularly the atypical forms with prominent permanent weakness or predominantly painful symptoms, remains incompletely characterized.
METHODS
A retrospective clinical, histological, electroneuromyography (ENMG) and genetic analysis of molecularly confirmed ATS patients, diagnosed and followed up at neuromuscular reference centers in France, was conducted.
RESULTS
Thirty-five patients from 27 unrelated families carrying 17 different missense KCNJ2 mutations (four novel mutations) and a heterozygous KCNJ2 duplication are reported. The typical triad was observed in 42.9% of patients. Cardiac abnormalities were observed in 65.7%: 56.5% asymptomatic and 39.1% requiring antiarrhythmic drugs. 71.4% of patients exhibited dysmorphic features. Muscle symptoms were reported in 85.7%, amongst whom 13.3% had no cardiopathy and 33.3% no dysmorphic features. Periodic paralysis was present in 80% and was significantly more frequent in men. Common triggers were exercise, immobility and carbohydrate-rich diet. Ictal serum potassium concentrations were low in 53.6%. Of the 35 patients, 45.7% had permanent weakness affecting proximal muscles, which was mild and stable or slowly progressive over several decades. Four patients presented with exercise-induced pain and myalgia attacks. Diagnostic delay was 14.4 ± 9.5 years. ENMG long-exercise test performed in 25 patients (71.4%) showed in all a decremental response up to 40%. Muscle biopsy performed in 12 patients revealed tubular aggregates in six patients (associated in two of them with vacuolar lesions), dystrophic features in one patient and non-specific myopathic features in one patient; it was normal in four patients.
DISCUSSION
Recognition of atypical features (exercise-induced pain or myalgia and permanent weakness) along with any of the elements of the triad should arouse suspicion. The ENMG long-exercise test has a high diagnostic yield and should be performed. Early diagnosis is of utmost importance to improve disease prognosis.

Identifiants

pubmed: 35460302
doi: 10.1111/ene.15369
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2398-2411

Informations de copyright

© 2022 European Academy of Neurology.

Références

Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105(4):511-519. doi:10.1016/S0092-8674(01)00342-7
Horga A, Rayan DLR, Matthews E, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472-1475. doi:10.1212/WNL.0b013e31828cf8d0
Stunnenberg BC, Raaphorst J, Deenen JCW, et al. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscul Disord. 2018;28(5):402-407. doi:10.1016/J.NMD.2018.03.006
Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies: a new syndrome? Acta Paediatrica. 1971;60(5):559-564. doi:10.1111/j.1651-2227.1971.tb06990.x
Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35(3):326-330. doi:10.1002/ana.410350313
Fialho D, Griggs RC, Matthews E. Periodic paralysis. Handb Clin Neurol. 2018;148:505-520. doi:10.1016/B978-0-444-64076-5.00032-6
Arzel-Hézode M, McGoey S, Sternberg D, Vicart S, Eymard B, Fontaine B. Glucocorticoids may trigger attacks in several types of periodic paralysis. Neuromuscul Disord. 2009;19(3):217-219. doi:10.1016/J.NMD.2008.12.008
Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med. 2004;36:92-97. doi:10.1080/17431380410032490
Davies NP, Imbrici P, Fialho D, et al. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology. 2005;65(7):1083-1089. doi:10.1212/01.wnl.0000178888.03767.74
Pérez-Riera AR, Barbosa-Barros R, Samesina N, et al. Andersen-Tawil syndrome: a comprehensive review. Cardiol Rev. 2021;29(4):165-177. doi:10.1097/CRD.0000000000000326
Nguyen HL, Pieper GH, Wilders R. Andersen-Tawil syndrome: clinical and molecular aspects. Int J Cardiol. 2013;170(1):1-16. doi:10.1016/j.ijcard.2013.10.010
Dolci C, Sansone VA, Gibelli D, Cappella A, Sforza C. Distinctive facial features in Andersen-Tawil syndrome: a three-dimensional stereophotogrammetric analysis. Am J Med Genet Part A. 2021;185(3):781-789. doi:10.1002/ajmg.a.62040
Yoon G, Quitania L, Kramer JH, Fu YH, Miller BL, Ptáček LJ. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. Neurology. 2006;66(11):1703-1710. doi:10.1212/01.wnl.0000218214.64942.64
Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56(5):650-661. doi:10.1002/ana.20241
Fournier E, Tabti N. Clinical electrophysiology of muscle diseases and episodic muscle disorders. Handb Clin Neurol. 2019;161:269-280. doi:10.1016/B978-0-444-64142-7.00053-9
Bendahhou S, Fournier E, Sternberg D, et al. In vivo and in vitro functional characterization of Andersen's syndrome mutations. J Physiol. 2005;565(3):731-741. doi:10.1113/jphysiol.2004.081620
Kimura H, Zhou J, Kawamura M, et al. Phenotype variability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet. 2012;5(3):344-353. doi:10.1161/CIRCGENETICS.111.962316
Kokubun N, Aoki R, Nagashima T, et al. Clinical and neurophysiological variability in Andersen-Tawil syndrome. Muscle Nerve. 2019;60(6):752-757. doi:10.1002/mus.26705
Mazzanti A, Guz D, Trancuccio A, et al. Natural history and risk stratification in Andersen-Tawil syndrome type 1. J Am Coll Cardiol. 2020;75(15):1772-1784. doi:10.1016/j.jacc.2020.02.033
Delannoy E, Sacher F, Maury P, et al. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace. 2013;15(12):1805-1811. doi:10.1093/europace/eut160
Miller TM, Dias Da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63(9):1647-1655. doi:10.1212/01.WNL.0000143383.91137.00
Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 Caucasian families. Am J Hum Genet. 1995;56(2):374-380.
Renner DR, Ptácek LJ. Periodic paralyses and nondystrophic myotonias. Adv Neurol. 2002;88:235-252.
Murphy LB, Schreiber-Katz O, Rafferty K, et al. Global FKRP registry: observations in more than 300 patients with limb girdle muscular dystrophy R9. Ann Clin Transl Neurol. 2020;7(5):757-766. doi:10.1002/acn3.51042
Libell EM, Richardson JA, Lutz KL, et al. Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related. Muscle Nerve. 2020;62(5):626-632. doi:10.1002/mus.27052
Song J, Luo S, Cheng X, et al. Clinical features and long exercise test in Chinese patients with Andersen-Tawil syndrome. Muscle Nerve. 2016;54(6):1059-1063. doi:10.1002/mus.25169
Fontaine B. Muscle channelopathies and related diseases. Handb Clin Neurol. 2013;113:1433-1436. doi:10.1016/B978-0-444-59565-2.00012-5
Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522. doi:10.1002/MUS.26009
Bendahhou S, Fournier E, Gallet S, Ménard D, Larroque MM, Barhanin J. Corticosteroid-exacerbated symptoms in an Andersen's syndrome kindred. Hum Mol Genet. 2007;16(8):900-906. doi:10.1093/hmg/ddm034
Yoon G, Oberoi S, Tristani-Firouzi M, et al. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype. Am J Med Genet. 2006;140A(4):312-321. doi:10.1002/ajmg.a.31092
Kostera-Pruszczyk A, Potulska-Chromik A, Pruszczyk P, et al. Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement. Muscle Nerve. 2015;51(2):192-196. doi:10.1002/mus.24293
Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002;110(3):381-388. doi:10.1172/JCI15183
Lefter S, Hardiman O, Costigan D, et al. Andersen-Tawil syndrome with early fixed myopathy. J Clin Neuromuscul Dis. 2014;16(2):79-82. doi:10.1097/CND.0000000000000052
Jurkat-Rott K, Weber MA, Fauler M, et al. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci USA. 2009;106(10):4036-4041. doi:10.1073/pnas.0811277106
Weber MA, Nielles-Vallespin S, Essig M, Jurkat-Rott K, Kauczor HU, Lehmann-Horn F. Muscle Na+ channelopathies: MRI detects intracellular 23Na accumulation during episodic weakness. Neurology. 2006;67(7):1151-1158. doi:10.1212/01.wnl.0000233841.75824.0f
Amarteifio E, Nagel AM, Weber MA, Jurkat-Rott K, Lehmann-Horn F. Hyperkalemic periodic paralysis and permanent weakness: 3-T MR imaging depicts intracellular 23Na overload-initial results. Radiology. 2012;264(1):154-163. doi:10.1148/radiol.12110980
Preisig-Müller R, Schlichthörl G, Goerge T, et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci USA. 2002;99(11):7774-7779. doi:10.1073/pnas.102609499
Seebohm G, Strutz-Seebohm N, Ursu ON, et al. Altered stress stimulation of inward rectifier potassium channels in Andersen-Tawil syndrome. FASEB J. 2012;26(2):513-522. doi:10.1096/fj.11-189126
Donaldson MR, Jensen JL, Tristani-Firouzi M, et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology. 2003;60(11):1811-1816. doi:10.1212/01.WNL.0000072261.14060.47
Eckhardt LL, Farley AL, Rodriguez E, et al. KCNJ2 mutations in arrhythmia patients referred for LQT testing: a mutation T305A with novel effect on rectification properties. Hear Rhythm. 2007;4(3):323-329. doi:10.1016/J.HRTHM.2006.10.025
Karschin C, Dißmann E, Stühmer W, Karschin A. IRK(1-3) and GIRK(1-4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci. 1996;16(11):3559-3570. doi:10.1523/jneurosci.16-11-03559.1996
Lam D, Schlichter LC. Expression and contributions of the Kir2.1 inward-rectifier K+ channel to proliferation, migration and chemotaxis of microglia in unstimulated and anti-inflammatory states. Front Cell Neurosci. 2015;9:185. doi:10.3389/fncel.2015.00185

Auteurs

Rocio Nur Villar-Quiles (RN)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Institute of Myology, Centre de Recherche en Myologie, UMRS974, Sorbonne Université - INSERM, Paris, France.

Damien Sternberg (D)

Reference Center for Muscle Channelopathies, Service de Biochimie et Centre de Génétique, APHP, Pitié-Salpêtrière Hospital, Paris, France.

Grégoire Tredez (G)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Norma Beatriz Romero (N)

Institute of Myology, Centre de Recherche en Myologie, UMRS974, Sorbonne Université - INSERM, Paris, France.
Neuromuscular Morphology Unit, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Teresinha Evangelista (T)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Institute of Myology, Centre de Recherche en Myologie, UMRS974, Sorbonne Université - INSERM, Paris, France.
Neuromuscular Morphology Unit, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Pascal Lafôret (P)

Reference Center for Neuromuscular Disorders, APHP, Raymond-Poincaré Hospital, Paris, France.

Pascal Cintas (P)

Neurology Department, Pierre-Paul Riquet Hospital, CHU Toulouse, Toulouse, France.

Guilhem Sole (G)

Reference Centre for Neuromuscular Disorders, Pellegrin Hospital CHU Bordeaux, Bordeaux, France.

Sabrina Sacconi (S)

Neuromuscular Diseases and ALS Specialized Center, University of Nice-Sophia Antipolis, Nice, France.

Said Bendahhou (S)

UMR7370 CNRS, LP2M, Labex ICST, Faculty of Medicine, University of Nice-Sophia Antipolis, Nice, France.

Jérôme Franques (J)

Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Neuromuscular Diseases, La Timone Hospital, Marseille, France.

Claude Cances (C)

AOC (Atlantique-Occitanie-Caraïbe) Reference Centre for Neuromuscular Disorders, Neuropediatric Department, Toulouse University Hospital, Toulouse, France.

J B Noury (JB)

Neurology Department, Neuromuscular Center, CHRU Cavale Blanche, Brest, France.

Emilien Delmont (E)

Department of Neurology, University Hospital Timone, Marseille, France.

Patricia Blondy (P)

Reference Center for Muscle Channelopathies, Service de Biochimie et Centre de Génétique, APHP, Pitié-Salpêtrière Hospital, Paris, France.

Laurence Perrin (L)

Pediatrics Department, APHP, Robert-Débré Hospital, Paris, France.

Marianne Hezode (M)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Emmanuel Fournier (E)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.

Bertrand Fontaine (B)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Institute of Myology, Centre de Recherche en Myologie, UMRS974, Sorbonne Université - INSERM, Paris, France.
Reference Center for Muscle Channelopathies, APHP, Institut de Myologie, Pitié-Salpêtrière Hospital, Paris, France.

Tanya Stojkovic (T)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Institute of Myology, Centre de Recherche en Myologie, UMRS974, Sorbonne Université - INSERM, Paris, France.

Savine Vicart (S)

Reference Center for Neuromuscular Disorders, APHP, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Reference Center for Muscle Channelopathies, APHP, Institut de Myologie, Pitié-Salpêtrière Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH